drugset / Trial / NCT01158157

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

NCT01158157

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).

Timeline

Start
2010-09-13
Primary completion
2012-02-14
Completion
2012-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM2000 Vaccine 2.5 ug Other

Indications